Predicted protein targets (top 2)
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL30611635 | 1.00 | SLC10A2 (0.43) | SLC10A2NR1H4 | |
| SCHEMBL22286643 | 1.00 | SLC10A2 (0.43) | SLC10A2NR1H4 | |
| SCHEMBL30540746 | 1.00 | SLC10A2 (0.43) | SLC10A2NR1H4 | |
| SCHEMBL22286487 | 1.00 | SLC10A2 (0.43) | SLC10A2NR1H4 | |
| SCHEMBL31051357 | 0.97 | SLC10A2 (0.42) | SLC10A2NR1H4 | |
| SCHEMBL22286569 | 0.97 | SLC10A2 (0.42) | SLC10A2NR1H4 | |
| SCHEMBL22314801 | 0.92 | SLC10A2 (0.38) | SLC10A2NR1H4 | |
| SCHEMBL22286405 | 0.92 | SLC10A2 (0.38) | SLC10A2NR1H4 | |
| SCHEMBL14559700 | 0.92 | SLC10A2 (0.45) | SLC10A2NR1H4 | |
| SCHEMBL6783221 | 0.92 | SLC10A2 (0.45) | SLC10A2NR1H4 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 32 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-3921027-B1 | BENZOTHIAZEPINE COMPOUNDS AND THEIR USE AS BILE ACID MODULATORS | ALBIREO AB (SE) | 2023-07-19 | — | — | EP | claimed |
| EP-3921027-A1 | BENZOTHIAZEPINE COMPOUNDS AND THEIR USE AS BILE ACID MODULATORS | Albireo AB (SE) | 2021-12-15 | — | — | EP | claimed |
| CN-113453753-A | Benzothiazepine compounds and their use as bile acid modulators | 阿尔比里奥公司 | 2021-09-28 | — | — | CN | claimed |
| US-10975045-B2 | Benzothiazepine compounds and their use as bile acid modulators | Aibireo AB (SE) | 2021-04-13 | — | — | US | claimed |
| WO-2020161216-A1 | BENZOTHIAZEPINE COMPOUNDS AND THEIR USE AS BILE ACID MODULATORS | ALBIREO AB (SE) | 2020-08-13 | — | — | WO | claimed |
| US-20200247768-A1 | BENZOTHIAZEPINE COMPOUNDS AND THEIR USE AS BILE ACID MODULATORS | ALBIREO AB (SE) | 2020-08-06 | — | — | US | claimed |
| US-20240207286-A1 | ASBT INHIBITORS IN THE TREATMENT OF RENAL DISEASES | ALBIREO AB (SE) | 2024-06-27 | — | — | US | disclosed |
| WO-2024121434-A1 | ASBT INHIBITORS IN THE TREATMENT OF RENAL DISEASES | ALBIREO AB (SE) | 2024-06-13 | — | — | WO | disclosed |
| US-20230338392-A1 | SUBCUTANEOUS ADMINISTRATION OF AN ASBT INHIBITOR | ALBIREO AB (SE) | 2023-10-26 | — | — | US | disclosed |
| WO-2023203248-A1 | SUBCUTANEOUS ADMINISTRATION OF AN ASBT INHIBITOR | ALBIREO AB (SE) | 2023-10-26 | — | — | WO | disclosed |
| US-11773071-B2 | Benzothiazepine compounds and their use as bile acid modulators | ALBIREO AB (SE) | 2023-10-03 | — | — | US | disclosed |
| US-11773071-B2 | Benzothiazepine compounds and their use as bile acid modulators | ALBIREO AB (SE) | 2023-10-03 | — | — | US | disclosed |
| US-11773071-B2 | Benzothiazepine compounds and their use as bile acid modulators | ALBIREO AB (SE) | 2023-10-03 | — | — | US | disclosed |
| EP-1345918-B1 | 1,5 BENZOTHIAZEPINES AND THEIR USE AS ANTIHYPERLIPIDEMICS | ASTRAZENECA AB (SE) | 2007-04-18 | — | — | EP | disclosed |
| US-7192945-B2 | Benzothiazepine derivatives | ASTRAZENECA AB (SE) | 2007-03-20 | — | — | US | disclosed |
| US-6906058-B2 | 1,5-Benzothiazepines and their use as hypolipidaemics | ASTRAZENECA AB (SE) | 2005-06-14 | — | — | US | disclosed |
| US-20040067933-A1 | Chemical compounds | ELOBIX AB (SE) | 2004-04-08 | — | — | US | disclosed |
| EP-1345918-A1 | CHEMICAL COMPOUNDS | AstraZeneca AB (SE) | 2003-09-24 | — | — | EP | disclosed |
| US-20030166927-A1 | 1,5-Benzothiazepines and their use as hypolipidaemics | ALBIREO AB (SE) | 2003-09-04 | — | — | US | disclosed |
| WO-2002050051-A1 | CHEMICAL COMPOUNDS | ASTRAZENECA AB (SE) | 2002-06-27 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (7 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-11773071-B2 | Benzothiazepine compounds and their use as bile acid modulators | SLC10A1, SLC10A2, ABCB11 | SLC10A2 2/4885NR1H4 6/4885 |
| US-20200247768-A1 | BENZOTHIAZEPINE COMPOUNDS AND THEIR USE AS BILE ACID MODULATORS | SLC10A1, SLC10A2, ABCB11 | SLC10A2 2/4885NR1H4 6/4885 |
| US-20040067933-A1 | Chemical compounds | SLC10A2, SLC10A1, ABCB11 | SLC10A2 1/4885NR1H4 7/4885 |
| US-20230338392-A1 | SUBCUTANEOUS ADMINISTRATION OF AN ASBT INHIBITOR | SLC10A1, SLC10A2, SLC10A6 | SLC10A2 2/4885NR1H4 5/4885 |
| US-20030166927-A1 | 1,5-Benzothiazepines and their use as hypolipidaemics | SLC10A2, SLC10A1, LCAT | SLC10A2 1/4885NR1H4 5/4885 |
| US-10975045-B2 | Benzothiazepine compounds and their use as bile acid modulators | SLC10A1, SLC10A2, ABCB11 | SLC10A2 2/4885NR1H4 6/4885 |
| US-20240207286-A1 | ASBT INHIBITORS IN THE TREATMENT OF RENAL DISEASES | SLC10A1, SLC10A2, ABCB11 | SLC10A2 2/4885NR1H4 5/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.